Basel Medical Group (BMGL)
Provides orthopedic, neurosurgical and primary-care services through Singapore clinics.
BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement
Singapore, July 10, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the "Company") today announced that it has received notification from Nasdaq that the Company has regained compliance with the Nasdaq minimum bid price rule. On January 22, 2026, Nasdaq notified the Company that its ordinary shares failed to maintain a minimum bid price of $1.
QingSong Health Corp (2661.HK) and Basel Medical Sign Strategic Cooperation Memorandum to Explore AI Healthcare Services in Southeast Asia
BEIJING, June 10, 2026 /PRNewswire/ -- Recently, QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties intend to explore cooperation in AI-enabled healthcare services, insurance-related healthcare solutions, and cross-border medical services in Southeast Asia.
BMGL to Effect Reverse Share Split on June 22, 2026
SINGAPORE, June 10, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the "Company"), a medical clinic operator in Singapore, today announced that the Company's board of directors has approved the consolidation of the Company's issued and outstanding shares of the Company on a 1-for-12 ratio with the marketplace effective date of June 22, 2026.
BMGL to Effect Reverse Share Split on June 22, 2026
SINGAPORE, June 10, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), a medical clinic operator in Singapore, today announced that the Company's board of directors has approved the consolidation of the Company's issued and outstanding shares of the Company on a 1-for-12 ratio with the marketplace effective date of June 22, 2026.
BMGL Investors Have Opportunity to Join Basel Medical Group Ltd Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Basel Medical Group Ltd (“Basel” or “the Company”) (NASDAQ: BMGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Rosen Law Firm Encourages Basel Medical Group Ltd. Investors to Inquire About Securities Class Action Investigation – BMGL
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.
Rosen Law Firm Encourages Basel Medical Group Ltd. Investors to Inquire About Securities Class Action Investigation – BMGL
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.
Basel Medical Group (NASDAQ:BMGL) Trading 1.5% Higher – Time to Buy?
Basel Medical Group Ltd (NASDAQ: BMGL - Get Free Report)'s share price was up 1.5% during trading on Monday. The company traded as high as $0.6703 and last traded at $0.6432. Approximately 41,958 shares changed hands during mid-day trading, a decline of 40% from the average daily volume of 70,156 shares. The stock had previously
Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company's initial public offering, has granted its consent on June 23, 2025 to the lock-up provision in the underwriting agreement dated February 24, 2025, permitting (i) a public offering or private placement of new securities of the Company, and (ii) the filing with the U.S. Securities and Exchange Commission of a registration statement under the Securities Act of 1933 in relation to such offering or placement, prior to the expiration of the lock-up period which was due to expire six months from the closing of the initial public offering.
Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility
Singapore, May 29, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today reaffirmed the strength of its underlying financial performance and strategic outlook, despite recent volatility in its share price.
Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities
Singapore, May 20, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that its subsidiary has been awarded a significant contract worth S$375 million by Pancare Technology International (HK) Limited to supply essential healthcare products in Asia-Pacific over the next five years until October 31, 2029. This milestone underscores the Company's commitment to delivering high-quality medical solutions and strengthening its global presence in the healthcare sector.
Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The acquisition marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market.
Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
Singapore, April 11, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the signing of a definitive agreement by its subsidiary Basel Medical Group Pte. Ltd. to acquire Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The agreement marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market. The completion of the acquisition is subject to customary closing conditions and is expected to take place on or around April 30, 2025 or such other date agreed by the parties.
Basel Medical Group Ltd Announces Exercise of Overallotment Option
Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the full exercise of the overallotment option by the representative of the underwriters of its initial public offering to purchase an additional 330,750 ordinary shares at a price of US$4.00 per share and the closing of such issuance. The shares of the Company commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”.
Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering
Singapore, March 03, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the closing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. The Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.